Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | USP1 | O94782 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | NRAS | P01111 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274336 | 1.00 | JAK2 (0.39) | JAK2JAK3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2274339 | 0.76 | BIRC2 (0.39) | JAK2JAK3KCNH2USP1FLT3 | |
| SCHEMBL2269372 | 0.76 | BIRC2 (0.39) | JAK2JAK3KCNH2USP1FLT3 | |
| SCHEMBL2269378 | 0.76 | BIRC2 (0.39) | JAK2JAK3KCNH2USP1FLT3 | |
| SCHEMBL14025152 | 0.71 | JAK2 (0.46) | JAK2JAK3USP1ALDH1A1 | |
| SCHEMBL12371656 | 0.70 | KDM1A (0.46) | JAK2JAK3USP1CYP3A4 | |
| SCHEMBL12371640 | 0.70 | KDM1A (0.46) | JAK2JAK3USP1CYP3A4 | |
| SCHEMBL12371633 | 0.70 | KDM1A (0.46) | JAK2JAK3USP1CYP3A4 | |
| SCHEMBL3852106 | 0.70 | ADORA3 (0.42) | USP1 | |
| SCHEMBL3845141 | 0.70 | USP1 (0.40) | USP1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2152708-A1 | PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | Pharmacopeia, LLC (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008143674-A1 | PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | JAK2 735/4885JAK3 719/4885SLC6A4 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.